The advanced age population (>65y) makes up ~20% of the total population in Europe, is the main carrier of chronic diseases and the major end-user group of medications. Yet, despite an ageing society, these end-users are entirely disregarded in the drug development proc...

The objective of the HELoS CSA is to support the Health.E Lighthouse Initiative Advisory Service (LIASE) in its ambition to accelerate innovation in medical devices (“Moore for Medical”). Health.E will accelerate the innovation in medical devices and systems by stimulat...

The ModLife project is a European Training Network initiative that brings together 5 leading European universities, 4 global industrial players and 2 SMEs to undertake research and training in the area of product-process innovation, optimization monitoring and control f...

Health and disease are regulated, to a large extent, by our immune system. The immune system not only protects the body from infectious disease, but is involved in a number of conditions of increasing incidence and morbidity, such as diabetes, rheumatoid arthritis, infl...

Oral drug products are preferred by hundreds of millions of patients in Europe. Yet, the challenges around formulating drugs for oral administration have increased tremendously over the last 30 years, mainly because most drugs coming through the Pharma pipeline are too ...